Desipramine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Desipramine

Examples of brand names: Norpramin [USA]

ATC code: N06AA01

Main use (for orientation): Depression

Documented research summary

There are pharmacodynamic animal findings for CBD: enhanced antidepressant-like effects in the mouse swim test and modified cardiovascular effects in a pithed rat model. No clinically quantified desipramine–cannabinoid interaction found. CYP2D6 inhibition and additive CNS/cardiovascular effects remain theoretical.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

3 separately recorded findings. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0350

Type of result: Preclinical

Observation: CBD 7 mg/kg plus desipramine 2.5 mg/kg showed an antidepressant-like effect in the mouse swim test at doses ineffective individually.

Mechanism: Preclinical pharmacodynamic modulation

Study type: Animal experiment

Context studied: Mouse model, acute combination; abstract read.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: No clinical depression or safety evidence; full-text access limited.

Original sources for this finding: Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. [BMED29885468]

CBD – laboratory and animal studies

Finding ID: B0351

Type of result: Preclinical

Observation: Desipramine reduced the CBD-induced increase in heart rate/systolic pressure and partly enhanced the fall in diastolic pressure.

Mechanism: Noradrenergic/cardiovascular modulation

Study type: Animal experiment

Context studied: Pithed WKY rats, desipramine 0.03–0.3 mg/kg, CBD 3/10 mg/kg intravenously; approximately 5–6 animals per group.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: CNS disabled; do not extrapolate to oral human treatment. Conscious rats showed no significant cardiovascular effect of CBD.

Original sources for this finding: Cannabidiol Affects the Bezold-Jarisch Reflex via TRPV1 and 5-HT3 Receptors and Has Peripheral Sympathomimetic Effects in Spontaneously Hypertensive and Normotensive Rats. [BMED31178718]

THC – laboratory and animal studies

Finding ID: B0352

Type of result: Preclinical

Observation: Desipramine 10 mg/kg subcutaneously did not alter THC-induced hypothermia in the mouse experiment investigated.

Mechanism: Animal-experiment null finding for a pharmacodynamic endpoint

Study type: Animal experiment

Context studied: Preclinical temperature measurement; abstract read.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: Endpoint-specific null finding, not general safety.

Original sources for this finding: Enhancement of the hypothermic response of mice to delta-9-tetrahydrocannabinol by subhypothermic doses of chlorpromazine and phentolamine. [C_PR_3035414]

References and access status

[C_LABEL_D0103] DESIPRAMINE HYDROCHLORIDE (DESIPRAMINE) TABLET, FILM COATED [AMNEAL PHARMACEUTICALS LLC]

Original source / bibliographic reference

Authors: AMNEAL PHARMACEUTICALS LLC

Year: 2026

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED31178718] Cannabidiol Affects the Bezold-Jarisch Reflex via TRPV1 and 5-HT3 Receptors and Has Peripheral Sympathomimetic Effects in Spontaneously Hypertensive and Normotensive Rats.

Original source / bibliographic reference

Authors: Kossakowski R, Schlicker E, Toczek M, Weresa J, Malinowska B.

Year: 2019

Source type: Preclinical primary study; full-text sections assessed

DOI: 10.3389/fphar.2019.00500

PMID: 31178718

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED29885468] Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels.

Original source / bibliographic reference

Authors: Sales AJ, Crestani CC, Guimarães FS, Joca SRL.

Year: 2018

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.pnpbp.2018.06.002

PMID: 29885468

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[C_PR_3035414] Enhancement of the hypothermic response of mice to delta-9-tetrahydrocannabinol by subhypothermic doses of chlorpromazine and phentolamine.

Original source / bibliographic reference

Authors: Gray GA, Hedley D, Pertwee RG.

Year: 1987

Source type: Primary source, abstract read

DOI: 10.1016/0028-3908(87)90213-9

PMID: 3035414

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility